#### In the claims

The following amendments are made with respect to the claims in the international application PCT/GB03/01375.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (original). A peptide having the amino acid sequence

### SCKNTDSRCKARQLELNERTCRCDKPRR

or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form.

- 2 (currently amended). A <u>The</u> peptide according to claim 1, which has the given sequence, in bicyclic form.
  - 3-6 (cancel).
- 7 (new). A pharmaceutical composition comprising a pharmaceutical carrier and a peptide having the amino acid sequence

# SCKNTDSRCKARQLELNERTCRCDKPRR

or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form.

8 (new). The pharmaceutical composition, according to claim 1, wherein the peptide has the given sequence, in bicyclic form.

9 (new). A method for stimulating nerve repair or treating neurodegeneration wherein said method comprises administering, to a patient in need of such stimulation or treatment, an effective amount or a peptide having the amino acid sequence

### SCKNTDSRCKARQLELNERTCRCDKPRR

or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form.

10 (new). The method, according to claim 9, wherein the peptide has the given sequence, in bicyclic form.

11 (new). A method for providing anti-cancer therapy, wherein said method comprises administering, to a patient in need of such therapy, an effective amount of a peptide having the amino acid sequence

## SCKNTDSRCKARQLELNERTCRCDKPRR

or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form.

12 (new). The method, according to claim 11, wherein the peptide has the given sequence, in bicyclic form.